NASDAQ:KRBP

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

Retrieved on: 
Wednesday, September 13, 2023
Health, Technology, Genetics, Artificial Intelligence, Pharmaceutical, Biotechnology, OTCQB, Intelligence, Failure, Galena Biopharma, Bank statement, OTC, Pink sheet, Security (finance)

The Company’s common stock will be quoted on the Pink Sheets platform operated by OTC Markets Group Inc. (the “OTC”) and will commence trading on September 14, 2023 at the market open under the “KRBP” ticker symbol.

Key Points: 
  • The Company’s common stock will be quoted on the Pink Sheets platform operated by OTC Markets Group Inc. (the “OTC”) and will commence trading on September 14, 2023 at the market open under the “KRBP” ticker symbol.
  • The Company’s stock will be quoted on the OTC Pink® Open Market while it pursues an uplisting to the OTCQB exchange.
  • Kiromic remains committed to maintaining transparency with its shareholders.
  • While the reporting requirements are different on the OTC Pink Sheets, the Company will continue to file regular financial statements and provide updates consistent with Nasdaq requirements and past practices.

Kiromic BioPharma Welcomes Two New Directors to its Board

Retrieved on: 
Monday, July 24, 2023
Biotechnology, Technology, Other Health, Health, General Health, Pharmaceutical, Oncology, Research, Artificial Intelligence, Science, Clinical Trials, Intelligence, Lung cancer, Audit committee, Medicine, Pharmaceutical industry, Management

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors.
  • Their regulatory and finance experience enhances Kiromic’s governance and re-establishes the Company’s five-member Board of Directors.
  • “We are delighted to welcome Pam and Michael to Kiromic’s Board.
  • I look forward to joining the Kiromic Board and contributing to their groundbreaking efforts in precision medicine.

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, May 1, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, GDT, Lung cancer, Intelligence, Breast, NSCLC, Colon, Prostate cancer, Patient, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Medical imaging

Notably, Deltacel does not require the use of any viral vector as many other cell therapies do, which, among other advantages, allows for reduced manufacturing costs.

Key Points: 
  • Notably, Deltacel does not require the use of any viral vector as many other cell therapies do, which, among other advantages, allows for reduced manufacturing costs.
  • Lung cancer is by far the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths.
  • “Receiving the authorization from the FDA to administer Deltacel to patients enables us to advance our GDT therapy candidate into the clinic.
  • “We are in the process of activating clinical trial sites, and we look forward to providing updates on our progress.”

Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer

Retrieved on: 
Monday, April 3, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Food, Lung cancer, Intelligence, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Patient, NSCLC, GDT, Cancer, Pharmaceutical industry

Deltacel is the Company’s allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cell (GDT) therapy.

Key Points: 
  • Deltacel is the Company’s allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cell (GDT) therapy.
  • The Company is seeking to address the significant unmet need of applying cell therapy to treat solid malignancies, which comprise 90% of all cancers, including NSCLC.
  • “Submitting this IND brings us one step closer to beginning human clinical testing with this incredible science and providing a promising treatment option to the tens of thousands of patients living with non-small cell lung cancer.
  • While this is the second most common type of cancer, lung cancer is the leading cause of cancer deaths in the United States, accounting for about 1 in 5 of all cancer deaths,” stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma.

Kiromic BioPharma Announces Reverse Stock Split

Retrieved on: 
Friday, March 10, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Bangladesh Securities and Exchange Commission, KRBP, Intelligence, Security (finance), CUSIP, Shareholder, Kiromal Katibin

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023.
  • As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 497634204.
  • Upon effectiveness of the reverse stock split, every 30 shares of Kiromic common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.
  • Immediately after the reverse stock split becomes effective, the Company will have approximately 966,758 shares of common stock issued and outstanding.

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results

Retrieved on: 
Tuesday, February 28, 2023
Other Health, Software, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Clinical Trials, Biotechnology, Stem Cells, Health, Trial of the century, Safety, IND, Mouse, Pharmacology, Data, Intelligence, Drug Efficacy Study Implementation, Pharmaceutical industry

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 (trademark: Deltacel™) administered alone and in combination with a non-biological anti-tumor therapy in mice.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 (trademark: Deltacel™) administered alone and in combination with a non-biological anti-tumor therapy in mice.
  • The histopathology report, authored by a certified veterinary pathologist, revealed no adverse microscopic findings related to the administration of Deltacel™ alone or as part of the combination treatment.
  • “We’re pleased to receive a clean pharmacology profile with no adverse findings and are encouraged by the preclinical results to-date in support of our planned IND submission.
  • This study completes the necessary dataset for authoring the Pharmacology Report of the Efficacy Study, which is an essential component of the nonclinical module of our IND application,” stated Leonardo Mirandola, Ph.D., Chief Scientific Officer of Kiromic BioPharma.

Lifshitz Law PLLC Announces Investigations of FMIA, SUMO, KRBP, and HYRE

Retrieved on: 
Sunday, February 26, 2023
Francisco Partners, Sale, Hewlett, FMIA, Telephone, Immunotherapy, Insurance, SUMO, Community, Advertising, KRBP, Financial adviser, Online shopping, United

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SUMO to affiliates of Francisco Partners for $12.05 per share in cash.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SUMO to affiliates of Francisco Partners for $12.05 per share in cash.
  • Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with possible false and misleading statements to investors concerning commercial prospects for the company’s immunotherapy medications.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with possible false and misleading statements to investors concerning HYRE’s insurance reserves.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals

Retrieved on: 
Thursday, February 23, 2023
Stem Cells, Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, Institutional Shareholder Services, Shareholder, Intelligence, Internet, Senior, Letter, ISS, Glass Lewis, Security (finance), Kiromal Katibin

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis), two leading independent proxy advisory firms, have issued recommendations that Kiromic stockholders vote FOR all three proposals at the Company’s Special Meeting of Stockholders being held March 7, 2023.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis), two leading independent proxy advisory firms, have issued recommendations that Kiromic stockholders vote FOR all three proposals at the Company’s Special Meeting of Stockholders being held March 7, 2023.
  • “The passage of each of these items is critically important to our ability to pursue the exciting business imperatives I outlined in a Letter to Stockholders that was published on February 16, 2023,” said Pietro Bersani, Chief Executive Officer of Kiromic BioPharma.
  • Voting instructions are contained in the proxy card; you can vote at any time via the internet, by mail, by phone, or in person at the meeting.
  • If stockholders have any questions or need assistance voting their shares, please contact Kiromic’s proxy solicitor:

Kiromic BioPharma CEO Issues Letter to Stockholders

Retrieved on: 
Thursday, February 16, 2023
Stem Cells, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Science, Clinical Trials, Toxicity, Stiris, Charles River Laboratories, MD Anderson Cancer Center, Mouse, Pharmacology, Investment, Cell engineering, Note, Safety, Patient, Clinical trial, Workforce, University, Senior, Letter, Special, Labcorp, Intelligence, Internet, FDA, Kiromal Katibin, Shareholder, IND, Medical imaging, Holding company, Pharmaceutical industry, Security (finance), Risk management

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today issued the following letter to stockholders from its CEO Pietro Bersani.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today issued the following letter to stockholders from its CEO Pietro Bersani.
  • On behalf of my hardworking colleagues at Kiromic BioPharma and our dedicated Board of Directors, I’d like to thank our stockholders for their continued support as we prepare for an exciting future together.
  • Importantly, Kiromic will host a Special Meeting of Stockholders on March 7th, 2023.
  • On behalf of the Kiromic team as well as our Board of Directors, I want to thank our stockholders for their continued support.

Kiromic BioPharma Arranges Up to $10 Million Financing

Retrieved on: 
Thursday, October 27, 2022
Research, Technology, Clinical Trials, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, U.S. Securities and Exchange Commission, NASDAQ, Terminology, LTD, Annual report, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, LinkedIn, Intelligence, Company, Partnership, SEPA, SEC, YA, Security (finance), Twitter, Kirom Bukhoroi

Kiromic separately also secured $2 million in gross proceeds from a new investor through the issuance of a secured convertible promissory note.

Key Points: 
  • Kiromic separately also secured $2 million in gross proceeds from a new investor through the issuance of a secured convertible promissory note.
  • The convertible note converts into the Companys common stock at a conversion price equal to $0.35 per share.
  • Following the close of the two financings, Kiromic also announced the completed settlement of its prior litigation with Sabby Capital Management, another institutional shareholder and certain affiliates.
  • Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid cancers.